List view / Grid view
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
Google has introduced an AI-powered 'co-scientist' designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
Professor Jens Christian Schwamborn is advancing personalised medicine for Parkinson’s disease using patient-specific brain organoids, offering new hope for more effective and targeted treatments.
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
The FORESIGHT consortium has secured €9 million to speed up drug development using advanced molecular imaging, targeting major diseases like cancer, autoimmune conditions, and heart disorders.
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Capgemini's new AI-powered methodology reduces data requirements by 99 percent and accelerates bioengineering breakthroughs, including improved plastic degradation and faster drug discovery.
An AI tool has identified adalimumab, a drug used for arthritis and Crohn’s disease, as a life-saving treatment for rare Castleman’s disease (iMCD). This finding offers hope for patients with the condition.
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
